Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Deutsche Bank Cuts Molecular Devices to 'Hold'

Deutsche Bank downgraded Molecular Devices (MDCC) to hold from buy.

Analyst Cheri Walker says the downgrade is based on valuation as Molecular Devices has risen 40% in the last month, vs. a 6% rise in the S&P 500, to well above her $14 target. She says the stock is trading at 31 times her 53 cents 2003 earnings per share estimate, vs. the average of roughly 20 times for peers.

Walker thinks Molecular Devices' stock shot up on the back of a recent positive report in Barron's, but she doesn't see any operational improvement that is substantial enough to warrant a premium to the group. She believes investors will find better value in Bio-Rad Labs, Invitrogen, Techne, and Fisher Scientific, which have higher visibility and lower valuations. She says Molecular Devices' fundamentals remain intact.

blog comments powered by Disqus